gilenya 0.5mg kapsula, tvrda
"novartis pharma services ag" dio stranog druŠtva podgorica - fingolimod - kapsula, tvrda - 0.5mg
mayzent 0.25mg film tableta
"novartis pharma services ag" dio stranog druŠtva podgorica - siponimod - film tableta - 0.25mg
mayzent 0.25mg film tableta
"novartis pharma services ag" dio stranog druŠtva podgorica - siponimod - film tableta - 0.25mg
mayzent 2mg film tableta
"novartis pharma services ag" dio stranog druŠtva podgorica - siponimod - film tableta - 2mg
mayzent 1mg film tableta
"novartis pharma services ag" dio stranog druŠtva podgorica - siponimod - film tableta - 1mg
mayzent 0,25 mg/1 tableta filmom obložena tableta
novartis ba d.o.o. - siponimod - filmom obložena tableta - 0,25 mg/1 tableta - jedna filmom obložena tableta sadrži: 0,25 mg siponimoda u obliku siponimod fumaratne kiseline
mayzent 0,25 mg/1 tableta filmom obložena tableta
novartis ba d.o.o. - siponimod - filmom obložena tableta - 0,25 mg/1 tableta - jedna filmom obložena tableta sadrži: 0,25 mg siponimoda u obliku siponimod fumaratne kiseline
mayzent 2 mg/1 tableta filmom obložena tableta
novartis ba d.o.o. - siponimod - filmom obložena tableta - 2 mg/1 tableta - jedna filmom obložena tableta sadrži: 2 mg siponimoda u obliku siponimod fumaratne kiseline
tysabri
biogen netherlands b.v. - natalizumab - multipla skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
tysabri 300 mg/15 ml koncentrat za rastvor za infuziju
medis international d.o.o. sarajevo - natalizumab - koncentrat za rastvor za infuziju - 300 mg/15 ml - 1 bočica sa 15 ml koncetrata za rastvor za infuziju sadrži: 300 mg natalizumaba